Phase I/II trial of AST-VAC2 in patients with non-small cell lung cancer.

Trial Profile

Phase I/II trial of AST-VAC2 in patients with non-small cell lung cancer.

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Sep 2017

At a glance

  • Drugs VAC 2 (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 26 Sep 2017 According to an Asterias Biotherapeutics media release, Medicines and Healthcare Products Regulatory Agency (MHRA) and the NHS Research Ethics Committee (REC) have provided the necessary approvals to initiate this study.
    • 14 Aug 2017 According to an Asterias Biotherapeutics media release, the company expects to initiation this trial in the second half of 2017.
    • 14 Nov 2016 According to an Asterias Biotherapeutics media release, preparation of a regulatory dossier to support execution of this study is underway with submission to the UK Medicines and Healthcare Products Agency (MHRA) planned early in the first quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top